β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells
- Noriyuki Sonoda,
- Takeshi Imamura,
- Takeshi Yoshizaki,
- Jennie L. Babendure,
- Juu-Chin Lu, and
- Jerrold M. Olefsky*
- Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, CA 92093
-
Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved February 29, 2008 (received for review November 1, 2007)
Abstract
Glucagon-like peptide-1 (GLP-1) is a polypeptide hormone secreted from enteroendocrine L cells and potentiates glucose-dependent insulin secretion in pancreatic β cells. Recently the GLP-1 receptor (GLP-1 R) has been a focus for new anti-diabetic therapy with the introduction of GLP-1 analogues and DPP-IV inhibitors, and this has stimulated additional interest in the mechanisms of GLP-1 signaling. Here we identify a mechanism for GLP-1 action, showing that the scaffold protein β-arrestin-1 mediates the effects of GLP-1 to stimulate cAMP production and insulin secretion in β cells. Using a coimmunoprecipitation technique, we also found a physical association between the GLP-1 R and β-arrestin-1 in cultured INS-1 pancreatic β cells. β-Arrestin-1 knockdown broadly attenuated GLP-1 signaling, causing decreased ERK and CREB activation and IRS-2 expression as well as reduced cAMP levels and impaired insulin secretion. However, β-arrestin-1 knockdown did not affect GLP-1 R surface expression and ligand-induced GLP-1 R internalization/desensitization. Taken together, these studies indicate that β-arrestin-1 plays a role in GLP-1 signaling leading to insulin secretion, defining a previously undescribed mechanism for GLP-1 action.
Footnotes
- *To whom correspondence should be addressed at: Department of Medicine (0673), University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0673. E-mail: jolefsky{at}ucsd.edu
-
Author contributions: N.S., T.I., and J.M.O. designed research; N.S., T.I., T.Y., J.L.B., and J.-C.L. performed research; N.S., T.I., and J.M.O. analyzed data; and N.S., T.I., and J.M.O. wrote the paper.
-
J.M.O. is a consultant for Pfizer Incorporated.
-
This article is a PNAS Direct Submission.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0710402105/DCSupplemental.
- © 2008 by The National Academy of Sciences of the USA





